Table 1.
Baseline characteristics of patients with estimated glomerular filtration rate (eGFR) <30 ml/min per 1.73 m2 or on renal replacement therapy (RRT) treated with remdesivir
| Baseline characteristics, n = 18 patients | n (%) or median (IQR) |
|---|---|
| Age, yr, median (IQR) | 68 (55–76) |
| Female, n (%) | 9 (50) |
| Race, n (%) | |
| White, Hispanic | 9 (50) |
| Black, non-Hispanic | 5 (28) |
| White, non-Hispanic | 4 (22) |
| Kidney function group, n (%) | |
| Stable CKD with eGFR <30 | 8 (44) |
| AKI, not on dialysisa | 5 (28) |
| AKI on RRT | 3 (17) |
| ESRD | 2 (11) |
| Creatinine at initiation of RDV, mg/dl, median (IQR) | |
| Stable CKD with eGFR <30 | 2.30 (1.79–2.81) |
| AKI, not on dialysis | 2.55 (1.79–2.92) |
| Comorbidities, n (%) | |
| CKD (eGFR <60 ml/min per 1.73 m2) | 16 (89) |
| ESRD | 2 (11) |
| Hypertension | 15 (83) |
| Diabetes mellitus | 9 (50) |
| Coronary artery disease | 5 (28) |
| Transplant recipient | 3 (17) |
| Chronic obstructive pulmonary disease | 2 (11) |
| Liver disease/cirrhosis | 1 (6) |
| BMI, median (IQR) | 28.6 (24.9–31) |
| Baseline medications, n (%) | |
| ACE inhibitors | 2 (11) |
| Angiotensin II receptor blockers | 2 (11) |
| Immunosuppression | 4 (22) |
| Diuretics | 5 (28) |
| Statins | 7 (39) |
| RDV dosing regimen prescribed, n (%)b | |
| 5-day course | 16 (89) |
| 10-day course | 2 (11) |
| RDV doses actually administered, n (%) | |
| 1 dose | 2 (11) |
| 3 doses | 2 (11) |
| 4 doses | 2 (11) |
| 5 doses | 11 (61) |
| 10 doses | 1 (6) |
| Days from symptom onset to RDV start, median (IQR) | 7 (3–10.5) |
| Adjuvant COVID-19 therapies used, n (%) | |
| Tocilizumab | 3 (17) |
| Canakinumab | 2 (11) |
| Dexamethasone | 4 (22) |
| Methylprednisolone/prednisone | 5 (28) |
| Convalescent plasma | 1 (6) |
| Labs at admission, median (IQR) | |
| Hemoglobin, g/dl | 11.0 (9.9–12.1) |
| D-dimer, ng/ml | 2196 (1145–3750) |
| Albumin, g/dl | 3.4 (2.7–3.8) |
| C-reactive protein, mg/l | 133.1 (59.3–221.0) |
| Location of admission, n (%) | |
| Intensive care unit | 11 (61) |
| Hospital floor | 7 (39) |
| Oxygen support required at baseline, n (%) | |
| Mechanical ventilation | 9 (50) |
| High-flow nasal cannula or nonrebreather | 3 (17) |
| Nasal cannula, ≤4 L | 6 (33) |
| On vasopressors at RDV start, n (%) | 6 (33) |
| On ECMO at RDV start, n (%) | 1 (6) |
ACE, angiotensin-converting enzyme; AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ESRD, end-stage renal disease; IQR, interquartile range; RDV, remdesivir.
a
Among the 8 patients meeting the definition of AKI, 6 also had baseline CKD.
b
All patients receive 200 mg i.v. bolus on day 1 followed by 100 mg/d. Remdesivir solution was used in 16 cases, and the powder formulation was used in 2 cases.